<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC3162661/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Eltrombopag increases plasma rosuvastatin exposure in
healthy volunteers</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC3162661/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers" />
<meta name="citation_authors" content=
"Alicia J Allred, Carolyn J Bowen, Jung Wook Park, Bin Peng, Daphne D Williams, Mary Beth Wire, Edmund Lee" />
<meta name="citation_date" content="August 2011" />
<meta name="citation_issue" content="2" />
<meta name="citation_volume" content="72" />
<meta name="citation_firstpage" content="321" />
<meta name="citation_doi" content=
"10.1111/j.1365-2125.2011.03972.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC3162661/?report=abstract" />
<meta name="citation_pmid" content="21434975" />
<meta name="DC.Title" content=
"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="Alicia J Allred" />
<meta name="DC.Contributor" content="Carolyn J Bowen" />
<meta name="DC.Contributor" content="Jung Wook Park" />
<meta name="DC.Contributor" content="Bin Peng" />
<meta name="DC.Contributor" content="Daphne D Williams" />
<meta name="DC.Contributor" content="Mary Beth Wire" />
<meta name="DC.Contributor" content="Edmund Lee" />
<meta name="DC.Date" content="2011 Aug" />
<meta name="DC.Identifier" content=
"10.1111/j.1365-2125.2011.03972.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"Eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, inhibits the organic anion transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP) in vitro. OATP1B1 is important for hepatic uptake of rosuvastatin and inhibition ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC3162661/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC3162661/pdf/bcp0072-0321.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"8A1A5178763004010000000000B911E2" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/199617/">v.72(2); 2011 Aug</a></li>
<li class="accid">PMC3162661</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2011 Aug; 72(2):
321–329.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1111%2Fj.1365-2125.2011.03972.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1111/j.1365-2125.2011.03972.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC3162661</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Eltrombopag increases plasma rosuvastatin
exposure in healthy volunteers</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Allred%20AJ%5Bauth%5D">Alicia J
Allred</a>,<sup>1</sup> <a href=
"/pubmed/?term=Bowen%20CJ%5Bauth%5D">Carolyn J
Bowen</a>,<sup>1</sup> <a href=
"/pubmed/?term=Park%20JW%5Bauth%5D">Jung Wook Park</a>,<sup>1</sup>
<a href="/pubmed/?term=Peng%20B%5Bauth%5D">Bin
Peng</a>,<sup>1</sup> <a href=
"/pubmed/?term=Williams%20DD%5Bauth%5D">Daphne D
Williams</a>,<sup>1</sup> <a href=
"/pubmed/?term=Wire%20MB%5Bauth%5D">Mary Beth Wire</a>,<sup>1</sup>
and <a href="/pubmed/?term=Lee%20E%5Bauth%5D">Edmund
Lee</a><sup>2</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id891633_ai" style="display:none">
<div class="fm-affl" lang="en"><sup>1</sup>GlaxoSmithKline, Five
Moore Drive, Research Triangle Park, NC, USA</div>
<div class="fm-affl" lang="en"><sup>2</sup>National University of
Singapore, 10 Medical Drive, Singapore 117597</div>
<div id="cor1">Director Mary Beth Wire PharmD, Clinical
Pharmacology, Modeling &amp; Simulation, GlaxoSmithKline, Five
Moore Drive, 17.1372A.2B, Research Triangle Park, NC 27709, USA.
Tel.: +1 919 483 5852 Fax: +1 919 483 8614 E-mail: <a href=
"mailto:dev@null" data-email="moc.ksg@eriw.b.yram" class=
"oemail">moc.ksg@eriw.b.yram</a></div>
<div id="__fnid863553">Dr. Park is now with Astellas, Three Parkway
North, Deerfield IL, USA; Dr. Peng is now with Novartis, 1 South
Ridgedale Ave, East Hanover, NJ, USA; Dr. Williams is now with
Bristol-Myers Squibb, Princeton, NJ, USA.</div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id891633_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id891633_an">Article notes
<span>►</span></a> <a href="#" class="pmctoggle" rid=
"id891633_cpl">Copyright and License information
<span>►</span></a></div>
<div class="fm-article-notes fm-panel hide half_rhythm" id=
"id891633_an" style="display:none">
<div class="fm-pubdate half_rhythm">Received 2010 Feb 28; Accepted
2011 Mar 21; Accepted 2011 Mar 25.</div>
</div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id891633_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2011 The British
Pharmacological Society</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC3162661/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid848652" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid848652title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>AIM</h3>
<p id="__p2" class="p p-first-last">Eltrombopag, an oral,
nonpeptide thrombopoietin receptor agonist, inhibits the organic
anion transporting polypeptide 1B1 (OATP1B1) and breast cancer
resistance protein (BCRP) <em>in vitro</em>. OATP1B1 is important
for hepatic uptake of rosuvastatin and inhibition of this
transporter could reduce cholesterol-lowering efficacy and increase
the risk of exposure-dependent toxicities. In contrast, BCRP is an
efflux transporter and inhibition of this transporter could
increase both hepatic and plasma rosuvastatin concentrations,
resulting in increased efficacy and toxicity. To determine if
co-administration of eltrombopag with rosuvastatin alters plasma
rosuvastatin exposure, an open-label study was conducted in 42
healthy adult subjects.</p>
</div>
<div id="__sec2" class="sec">
<h3>METHODS</h3>
<p id="__p3" class="p p-first-last">Subjects received rosuvastatin
and eltrombopag orally: day 1, rosuvastatin 10 mg single dose; days
6 to 9, eltrombopag 75 mg once daily; day 10, eltrombopag 75 mg
once daily and rosuvastatin 10 mg single dose. Adverse event
assessments were performed daily and at the follow-up visit. Plasma
samples for pharmacokinetic analysis were collected days 1 to 5 and
days 10 to 14.</p>
</div>
<div id="__sec3" class="sec">
<h3>RESULTS</h3>
<p id="__p4" class="p p-first-last">Co-administration of
eltrombopag with rosuvastatin increased geometric mean (90%
confidence interval) plasma rosuvastatin AUC(0,∞) by 55% (42%, 69%)
and <em>C</em><sub>max</sub> by 103% (82%, 126%) in the overall
study population, with a larger interaction in the non-Asian
compared with Asian subjects.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>CONCLUSIONS</h3>
<p id="__p5" class="p p-first-last">Concomitant administration of
eltrombopag with rosuvastatin was associated with increased
rosuvastatin exposure. The therapeutic index of HMG Co-A reductase
inhibitors may be reduced by the concomitant use of eltrombopag. In
subjects taking eltrombopag, a reduced dose of HMG Co-A reductase
inhibitors may be needed.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">BCRP, drug interaction, eltrombopag,
OATP1B1, rosuvastatin</span></div>
</div>
<div id="__bodyid573990" class="tsec sec headless whole_rhythm">
<div class="boxed-text-box whole_rhythm hide-overflow">
<div class="sec">
<h3>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT</h3>
<ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
-->
<li>
<div>OATP1B1 is important for hepatic uptake of rosuvastatin and
BCRP is important for rosuvastatin absorption and elimination.
Eltrombopag inhibits OATP1B1 and BCRP <em>in vitro</em> at
clinically relevant concentrations. Inhibition of these
transporters could change cholesterol-lowering efficacy and
increase the risk of exposure-dependent toxicities. To determine if
co-administration of eltrombopag with rosuvastatin alters plasma
rosuvastatin exposure, an open-label study was conducted in 42
healthy adult subjects.</div>
</li>
</ul>
</div>
</div>
<div class="boxed-text-box whole_rhythm hide-overflow">
<div class="sec">
<h3>WHAT THIS STUDY ADDS</h3>
<ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
-->
<li>
<div>Concomitant administration of eltrombopag with rosuvastatin
was associated with increased rosuvastatin exposure via inhibition
of drug transporters. The therapeutic index of HMG Co-A reductase
inhibitors may be reduced by the concomitant use of eltrombopag. In
subjects taking eltrombopag, a reduced dose of HMG Co-A reductase
inhibitors may be needed.</div>
</li>
</ul>
</div>
</div>
</div>
<div id="__sec7" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec7title">
Introduction</h2>
<p id="__p8" class="p p-first">Eltrombopag (GlaxoSmithKline) is an
oral, nonpeptide thrombopoietin receptor agonist approved for the
treatment of chronic immune thrombocytopenia (ITP). It is also
being investigated for the treatment of thrombocytopenia due to
other aetiologies including chronic liver disease and hepatitis C
virus [<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901777">1</a>–<a href="#b3" rid="b3" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901804">3</a>]. Eltrombopag binds to the transmembrane
domain of the thrombopoietin receptor and increases platelet counts
by stimulating proliferation and differentiation of megakaryocytes
[<a href="#b4" rid="b4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901785">4</a>].</p>
<p id="__p9">In preclinical studies, eltrombopag inhibited the
organic anion transporting polypeptide 1B1 (OATP1B1) and breast
cancer resistance protein (BCRP). Eltrombopag was also identified
as a BCRP substrate <em>in vitro</em>. OATP1B1 is highly expressed
in the liver and involved in the hepatic uptake of all HMG-CoA
reductase inhibitors (statins) [<a href="#b5" rid="b5" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901788">5</a>]. OATP1B1 is important for rosuvastatin
disposition as demonstrated by genetic polymorphism, where subjects
with the homozygous OATP1B1 (<em>SLCO1B1</em>) c.521CC genotype had
65% higher rosuvastatin mean area under the curve (AUC(0,48 h))
than those with the homozygous c.521TT (control) genotype [<a href=
"#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901783">6</a>]. The OATP1B1 (<em>SLCO1B1</em>) c.388GG
genotype in combination with the c.521CC genotype
(<em>SLCO1B1</em>*<em>15/</em>*<em>15</em>) has also been
associated with higher plasma rosuvastatin exposure [<a href="#b7"
rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901790">7</a>]. BCRP is an efflux transporter that
transports drugs from the liver into bile and also limits
intestinal drug absorption. BCRP is important for rosuvastatin
disposition as demonstrated by genetic polymorphism, where subjects
with the heterozygous BCRP (<em>ABCG2</em>) c.421CA or homozygous
c.421AA genotypes had approximately two-fold the rosuvastatin
AUC(0,∞) compared with those with the homozygous c.421CC (control)
genotype [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901800">8</a>,
<a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901803">9</a>]. The <em>ABCG2</em> c.421AA genotype was
associated with greater reductions in low-density lipoprotein (LDL)
cholesterol in subjects receiving rosuvastatin therapy [<a href=
"#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901792">10</a>].</p>
<p id="__p10" class="p p-last">Rosuvastatin has known
transporter-mediated drug interactions, such as its interaction
with gemfibrozil and cyclosporin [<a href="#b11" rid="b11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901778">11</a>, <a href="#b12" rid="b12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901805">12</a>]. The objective of this study was to
evaluate the impact of eltrombopag on plasma rosuvastatin
exposure.</p>
</div>
<div id="__sec8" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec8title">Methods</h2>
<div id="__sec9" class="sec sec-first">
<h3>Study design</h3>
<p id="__p11" class="p p-first">An open-label, single sequence
study was conducted at clinical research sites in Singapore and the
United States in 42 healthy adult men and women. All subjects
provided written, informed consent. Subjects received rosuvastatin
and eltrombopag orally in the following sequence: day 1,
rosuvastatin 10 mg single dose; day 6 through day 9, eltrombopag 75
mg once daily; day 10, eltrombopag 75 mg once daily and
rosuvastatin 10 mg single dose. This study was designed and
monitored in accordance with Good Clinical Practice and the
Declaration of Helsinki. The individual Institutional Review Boards
at each study site approved the protocol before the study
started.</p>
<p id="__p12">To ensure treatment compliance and continuous safety
monitoring, subjects received all doses of study drugs at the
clinical research centre and remained in the clinical research unit
from day −1 through day 5 and from days 10 through 14. Subjects
returned for a follow-up visit approximately 7 to 14 days after the
last dose of study medication. The duration of each individual's
participation in the study from initial screening to follow-up was
approximately 4 weeks.</p>
<p id="__p13">Inclusion criteria required that participants be
healthy. Male and non-pregnant female subjects 18 to 64 years
weighing at least 50 kg for men and 45 kg for women were eligible
for enrolment. Candidates were ineligible if they had any
clinically relevant abnormality identified by prestudy screening
history, physical examination, or laboratory testing, including
electrocardiogram (ECG) abnormalities, cardiovascular or
coagulation disorders, evidence of drug or alcohol abuse or tobacco
use, a positive test for HIV, hepatitis B or hepatitis C virus, or
use of prescription or non-prescription medications within 7 days
(14 days for enzyme-inducing drugs) before receiving the first dose
of study drug.</p>
<p id="__p14" class="p p-last">Adverse event (AE) assessments were
performed daily for the duration of the study and at the follow-up
visit. Standard meals were provided on study day −1 to day 5 and
days 10 to 14. Participants fasted 8 h before and 4 h after
administration of either study drug. Serial 3 ml blood samples for
pharmacokinetic (PK) analysis were collected prior to and 0.5, 1,
1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after
single dose rosuvastatin administration on days 1 and 10. A blood
sample was obtained on day −1 for the purpose of genotyping the
OATP1B1 (<em>SLCO1B1</em>), BCRP (<em>ABCG</em>2) and NTCP [sodium
taurocholate co-transporting polypeptide (<em>SLC10A1</em>)]
transporters.</p>
</div>
<div id="__sec10" class="sec sec-last">
<h3>Analyses</h3>
<p id="__p15" class="p p-first">Genotyping for polymorphisms in
OATP1B1 (<em>SLCO1B1</em>) T521C and A388G and BCRP
(<em>ABCG2</em>) C421A and NTCP (<em>SLC10A1</em>) exon 3 *3 and
exon 4 *2, *4, and *5 was done. Regions spanning the single
nucleotide polymorphisms (SNPs) of interest were first amplified
from genomic DNA via polymerase chain reaction (PCR) using specific
primers as presented in <a href=
"/pmc/articles/PMC3162661/table/tbl1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>. PCR product
sizes and purity were confirmed by agarose gel electrophoresis
against a 100 base pair (bp) molecular weight marker.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC3162661/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC3162661/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC3162661/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC3162661/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>Primer sequences</span></div>
</div>
</div>
<p id="__p18">For OATP1B1 (<em>SLCO1B1</em>) T521C and A388G, and
NTCP (<em>SLC10A1</em>) exon 3 *3 and exon 4 *2, *4, and *5, the
amplified fragments were subsequently analyzed by bidirectional
sequencing using Bigdye V3.1 termination cycle sequencing kit
(Applied Biosystems, Foster City, CA) on an ABI Avant 3100 genetic
analyzer (Applied Biosystems). All polymorphisms were called using
mutation analysis software (Mutation Surveyor V5.1) and qualified
additionally by predetermined sample controls.</p>
<p id="__p19">The BCRP (<em>ABCG2</em>) C421A polymorphism was
genotyped by Taa I PCR restriction fragment length polymorphism.
Briefly, the amplified 289 bp PCR fragment encompassing the SNP of
interest was subsequently incubated at 65°C with three units of a
restriction enzyme (Taa I) for 3 h. The digested amplified products
were loaded onto a 3% agarose gel to verify digested product sizes.
A wt/wt (cc/cc) genotype would reveal a digested product size of
256 bp whereas a mt/mt (aa/aa) genotype would resist digestion by
the enzyme to remain at 289 bp. Heterozygous genotypes exhibit both
product sizes (289 bp and 256 bp).</p>
<p id="__p20">Plasma PK samples collected on days 1 and 10 were
assayed for rosuvastatin using a validated analytical method based
on solid phase extraction, followed by high-performance liquid
chromatography coupled to tandem mass spectrometry (HPLC/MS/MS)
analysis. Using a 100 µl aliquot of plasma, the lower limit of
quantification for the rosuvastatin assay was 0.2 ng
ml<sup>−1</sup> and the higher limit of quantification was 30 ng
ml<sup>−1</sup>. Each batch of plasma samples was run against
freshly prepared duplicate calibration standards (<em>n</em> = 8).
Imprecision and inaccuracy between assays were &lt;14%. Quality
control (QC) samples at three concentrations (0.5, 5, and 25 ng
ml<sup>−1</sup>) were assayed along with study samples and the
calculated QC sample concentrations deviated by &lt;15% from the
actual concentrations. Plasma PK samples collected on day 10 were
assayed for eltrombopag using a validated analytical method based
on protein precipitation, followed by HPLC/MS/MS analysis. Using a
50 µl aliquot of plasma, the lower limit of quantification for the
eltrombopag assay was 100 ng ml<sup>−1</sup> and the higher limit
of quantification was 50 000 ng ml<sup>−1</sup>. Each batch of
plasma samples was run against freshly prepared duplicate
calibration standards (<em>n</em> = 9). Imprecision and inaccuracy
between assays were &lt;14%. QC samples at three concentrations
(400, 4000, and 40 000 ng ml<sup>−1</sup>) were assayed along with
study samples and the calculated QC sample concentrations deviated
by &lt;15% from the actual concentrations.</p>
<p id="__p21">The primary PK endpoints were maximum plasma
concentration (<em>C</em><sub>max</sub>) and area under the plasma
concentration <em>vs</em>. time curve starting from dosing and
extrapolated to infinity (AUC(0,∞)) of rosuvastatin when
administered alone or co-administered with eltrombopag.
<em>C</em><sub>max</sub> and the first time to reach
<em>C</em><sub>max</sub> (<em>t</em><sub>max</sub>) were the actual
observed values. The AUC was calculated using the linear
trapezoidal rule for each incremental trapezoid and the log
trapezoidal rule for each decremental trapezoid. The AUC from time
zero to the last measurable concentration (AUC(0,τ)) and AUC(0,∞)
was determined. Values for AUC(0,∞) were estimated as the sum of
AUC(0,τ) and <em>C<sub>t</sub></em> divided by the elimination rate
constant (λ<sub>z</sub>), where <em>C<sub>t</sub></em> was the last
observed quantifiable concentration.</p>
<p id="__p22">Steady-state plasma eltrombopag
<em>C</em><sub>max</sub> and AUC over a dosing interval (AUC(0,τ))
were estimated for the combination regimen only. In addition,
plasma eltrombopag trough concentrations collected on day 10 prior
to administration of rosuvastatin and 24 h after rosuvastatin
co-administration were measured.</p>
<p id="__p23">To assess the effects of eltrombopag on rosuvastatin
PK, log transformed plasma rosuvastatin AUC(0,∞) and
<em>C</em><sub>max</sub> were analyzed separately by analysis of
variance (<span class="small-caps">anova</span>) fitting terms for
treatment and subject. Point estimates and associated 90%
confidence intervals (CI) for the differences were constructed
using the appropriate error term. The point and interval estimates
on the log scale were then back-transformed to give point and
interval estimates for the ratios. Plasma eltrombopag and
rosuvastatin PK parameters were summarized by treatment and by race
and gender within treatment. Plasma rosuvastatin concentration–time
profiles were plotted by treatment, race and gender. Plasma
rosuvastatin AUC(0,∞) was plotted by genotype combination (approach
2 as described in the following paragraph). Subgroup analyses were
conducted as secondary analyses. Similar to the primary statistical
analysis, plasma rosuvastatin PK values were compared between
treatments for subgroups based on race (Asian <em>vs.</em>
non-Asian) and gender.</p>
<p id="__p24" class="p p-last">Multivariate analyses of the
relationship between day 1 plasma rosuvastatin AUC(0,∞) and
<em>C</em><sub>max</sub> and potential covariates was completed.
The analysis included race (Asian <em>vs.</em> non-Asian), gender,
body weight, and OATP1B1 (<em>SLCO1B1</em>) A388G and T521C and
BCRP (<em>ABCG2</em>) C421A genotypes. Genotypes were included
three ways. Approach 1: each gene variant was included separately.
Approach 2: <em>SLCO1B1</em> haplotype and <em>ABCG2</em> genotype
combinations were categorized, Category 1 included <em>SLCO1B1</em>
haplotypes *1a/*1a, *1a/*1b, and *1b/*1b, Category 2 included
<em>SLCO1B1</em> haplotypes *1a/*15 and *1b/*15, Category 3
included the <em>ABCG2</em> c.421CA genotype in combination with
<em>SLCO1B1</em> haplotypes *1a/*1a, *1a/*1b, or *1b/*1b and
Category 4 included the <em>ABCG2</em> c.421CA genotype in
combination with <em>SLCO1B1</em> haplotypes *1b/*15 or *15/*15 and
the <em>ABCG2</em> c.421AA genotype in combination with
<em>SLCO1B1</em> haplotype *1b/*1b. Approach 3: combinations of
gene variants c.388AA, c.388AG, c.521TT, c.521TC and c.421CC were
assigned zero, c.388GG, c.521CC and c.421CA were assigned 1 and
c.421AA was assigned 2, and the scores were summed across the three
gene variants (possible score of 0 to 4).</p>
</div>
</div>
<div id="__sec11" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec11title">Results</h2>
<div id="__sec12" class="sec sec-first">
<h3>Demographics and genotypes</h3>
<p id="__p25" class="p p-first">Similar numbers of Asian and
non-Asian subjects were enrolled in the study (<a href=
"/pmc/articles/PMC3162661/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). Of the
genotypes evaluated in the current study, only the OATP1B1
(<em>SLCO1B1</em>) A388G genotypes were relatively evenly
distributed overall and within Asian and non-Asian groups (<a href=
"/pmc/articles/PMC3162661/table/tbl3/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob=
"ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). The majority
of subjects had homozygous wild-type OATP1B1 (<em>SLCO1B1</em>)
c.521TT and BCRP (<em>ABCG2</em>) c.421CC genotypes, with 20 to 40%
having the heterozygous genotype (<a href=
"/pmc/articles/PMC3162661/table/tbl3/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob=
"ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). There was a
broad range of OATP1B1 (<em>SLCO1B1</em>) haplotype and BCRP
(<em>ABCG2</em>) genotype combinations (<a href=
"/pmc/articles/PMC3162661/table/tbl3/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob=
"ob-tbl3" co-legend-rid=""><span>Table 3</span></a>).</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl2"><a href="/pmc/articles/PMC3162661/table/tbl2/" target=
"table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class=
"table img_link icnblk_img figpopup"><img alt="Table 2" title=
"Table 2" class="small-thumb" src=
"/pmc/articles/PMC3162661/table/tbl2/?report=thumb" src-large=
"/pmc/articles/PMC3162661/table/tbl2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC3162661/table/tbl2/" target="table" rid-figpopup=
"tbl2" rid-ob="ob-tbl2">Table 2</a></div>
<!--caption a4-->
<div><span>Subject disposition and demographics</span></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl3"><a href="/pmc/articles/PMC3162661/table/tbl3/" target=
"table" rid-ob="ob-tbl3" rid-figpopup="tbl3" class=
"table img_link icnblk_img figpopup"><img alt="Table 3" title=
"Table 3" class="small-thumb" src=
"/pmc/articles/PMC3162661/table/tbl3/?report=thumb" src-large=
"/pmc/articles/PMC3162661/table/tbl3/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC3162661/table/tbl3/" target="table" rid-figpopup=
"tbl3" rid-ob="ob-tbl3">Table 3</a></div>
<!--caption a4-->
<div><span>Summary of genotype frequency</span></div>
</div>
</div>
</div>
<div id="__sec13" class="sec">
<h3>Pharmacokinetics</h3>
<p id="__p31" class="p p-first">Race (<em>P</em> &lt; 0.001) and
gender (<em>P</em> &lt; 0.05) were retained as significant
predictors of plasma rosuvastatin AUC(0,∞) and
<em>C</em><sub>max</sub> in the final multivariate models where
genotype by approach 1 and approach 2 were tested. Race (<em>P</em>
&lt; 0.001), gender (<em>P</em> &lt; 0.05) and genotype (<em>P</em>
&lt; 0.05) were retained in the final model as significant
predictors of plasma rosuvastatin AUC(0,∞) and
<em>C</em><sub>max</sub> where genotype by approach 3 was tested.
Body weight was not a significant covariate in any of the analyses.
Only one of 21 Asian subjects was female, so the gender effect was
driven by data within the non-Asian group (seven of 18 non-Asian
subjects were female). Asian participants had a 109% higher
rosuvastatin AUC(0,∞) and a 139% higher <em>C</em><sub>max</sub>
compared with non-Asian subjects when rosuvastatin was administered
alone (<a href="/pmc/articles/PMC3162661/table/tbl4/" target="true"
class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). Within the
non-Asian population, female participants had 50% higher
rosuvastatin AUC(0,∞) and 84% higher <em>C</em><sub>max</sub>
compared with male subjects when rosuvastatin was administered
alone.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl4"><a href="/pmc/articles/PMC3162661/table/tbl4/" target=
"table" rid-ob="ob-tbl4" rid-figpopup="tbl4" class=
"table img_link icnblk_img figpopup"><img alt="Table 4" title=
"Table 4" class="small-thumb" src=
"/pmc/articles/PMC3162661/table/tbl4/?report=thumb" src-large=
"/pmc/articles/PMC3162661/table/tbl4/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC3162661/table/tbl4/" target="table" rid-figpopup=
"tbl4" rid-ob="ob-tbl4">Table 4</a></div>
<!--caption a4-->
<div><span>Summary of plasma rosuvastatin pharmacokinetics and
treatment comparisons</span></div>
</div>
</div>
<p id="__p37">Co-administration of eltrombopag with rosuvastatin
increased plasma rosuvastatin AUC(0,∞) by 55% and
<em>C</em><sub>max</sub> by 103% in the overall study population
compared with administration of rosuvastatin alone (<a href=
"/pmc/articles/PMC3162661/table/tbl4/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). The impact of
eltrombopag on plasma rosuvastatin exposure differed by race.
Plasma rosuvastatin AUC(0,∞) increased by 88% and
<em>C</em><sub>max</sub> increased 165% in non-Asian subjects,
whereas AUC(0,∞) increased by 32% and <em>C</em><sub>max</sub>
increased 61% in Asian subjects (<a href=
"/pmc/articles/PMC3162661/table/tbl4/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). Median plasma
rosuvastatin concentration–time profiles are displayed for the
overall population and by race for each treatment in <a href=
"/pmc/articles/PMC3162661/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>.
The impact of eltrombopag on plasma rosuvastatin exposure appeared
to differ by gender within the non-Asian population (<a href=
"/pmc/articles/PMC3162661/table/tbl4/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC3162661/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC3162661/bin/bcp0072-0321-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC3162661/bin/bcp0072-0321-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC3162661/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Median plasma rosuvastatin concentration–time profiles.
rosuvastain alone (no symbol = rosuvastain + eltrombopag) (▴);
overall population (<img alt=
"An external file that holds a picture, illustration, etc. Object name is bcp0072-0321-mu1.jpg"
src="/pmc/articles/PMC3162661/bin/bcp0072-0321-mu1.jpg" class=
"equation" />); Asian (<img alt=
"An external file that holds a picture, illustration, etc. Object name is bcp0072-0321-mu2.jpg"
src="/pmc/articles/PMC3162661/bin/bcp0072-0321-mu2.jpg" class=
"equation" />); non-Asian (<img alt=
"An external file that holds a picture, illustration, etc. Object name is bcp0072-0321-mu3.jpg"
src="/pmc/articles/PMC3162661/bin/bcp0072-0321-mu3.jpg" class=
"equation" />)</span></div>
</div>
</div>
<p id="__p39">Subjects with combined genotype scores (approach 3)
of 2–3 had higher plasma rosuvastatin exposures than subjects with
scores of 0–1, and there was also a trend for higher plasma
rosuvastatin exposures for subjects in category 4 (approach 2).
However, given the small sample size, it is difficult to draw firm
conclusions regarding the relationship between genotype and plasma
rosuvastatin exposure. Plasma rosuvastatin AUC(0,∞) <em>vs</em>.
genotype combination (approach 2) are displayed in <a href=
"/pmc/articles/PMC3162661/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>,
along with race and gender details.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC3162661/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC3162661/bin/bcp0072-0321-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC3162661/bin/bcp0072-0321-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC3162661/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>Plasma rosuvastatin AUC(0,∞) by OATP1B1
(<em>SLCO1B1</em>) haplotype and BCRP (<em>ABCG2</em>) C421A
genotype. non-Asian male (□); Asian male (○); non-Asian female
(<img alt=
"An external file that holds a picture, illustration, etc. Object name is bcp0072-0321-mu4.jpg"
src="/pmc/articles/PMC3162661/bin/bcp0072-0321-mu4.jpg" class=
"equation" />); Asian female (•)</span></div>
</div>
</div>
<p id="__p41" class="p">For the overall population, the geometric
mean of plasma eltrombopag <em>C</em><sub>max</sub> was 8.00 µg
ml<sup>−1</sup> and AUC(0,τ) was 102 µg ml<sup>−1</sup> h, and
plasma eltrombopag exposures were similar between Asian and
non-Asian subjects and between the BCRP (<em>ABCG2</em>) c.421CC
and c.421CA genotypes (<a href=
"/pmc/articles/PMC3162661/table/tbl5/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl5" rid-ob=
"ob-tbl5" co-legend-rid=""><span>Table 5</span></a>). The one
subject (Asian male) with the c.421AA genotype had the highest
plasma eltrombopag AUC(0,τ) (247 µg ml<sup>−1</sup> h), but the
exposure was similar to the highest AUC(0,τ) (227 µg
ml<sup>−1</sup> h) observed for an Asian male subject with the
c.421CC genotype. When races were combined, plasma eltrombopag
exposure was similar between males and females (<a href=
"/pmc/articles/PMC3162661/table/tbl5/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl5" rid-ob=
"ob-tbl5" co-legend-rid=""><span>Table 5</span></a>), but within
the non-Asian group, women had approximately 46% higher plasma
eltrombopag AUC(0,τ) (126 <em>vs.</em> 86 µg ml<sup>−1</sup> h) and
37% higher <em>C</em><sub>max</sub> (9.48 <em>vs.</em> 6.94 µg
ml<sup>−1</sup>). Median (range) eltrombopag trough concentrations
of 2.98 µg ml<sup>−1</sup> (1.14–6.97 µg ml<sup>−1</sup>) collected
on day 10 prior to co-administration of rosuvastatin were similar
to trough concentrations of 3.22 µg ml<sup>−1</sup> (1.22–6.94 µg
ml<sup>−1</sup>) collected 24 h after co-administration of a single
dose of rosuvastatin.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl5"><a href="/pmc/articles/PMC3162661/table/tbl5/" target=
"table" rid-ob="ob-tbl5" rid-figpopup="tbl5" class=
"table img_link icnblk_img figpopup"><img alt="Table 5" title=
"Table 5" class="small-thumb" src=
"/pmc/articles/PMC3162661/table/tbl5/?report=thumb" src-large=
"/pmc/articles/PMC3162661/table/tbl5/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC3162661/table/tbl5/" target="table" rid-figpopup=
"tbl5" rid-ob="ob-tbl5">Table 5</a></div>
<!--caption a4-->
<div><span>Summary of plasma eltrombopag
pharmacokinetics</span></div>
</div>
</div>
</div>
<div id="__sec14" class="sec sec-last">
<h3>Safety</h3>
<p id="__p45" class="p p-first-last">AEs were reported by 10% to
21% of subjects per treatment. AEs reported by more than one
subject on a given treatment included gastroenteritis, headache and
upper respiratory infection. No serious AEs were reported by study
participants. Subjects experienced no clinically significant
changes in vital signs, ECG abnormalities or QT<sub>c</sub>
prolongation. Increased platelet counts were observed in several
subjects following administration of eltrombopag. At the follow-up
visit, 16 subjects (38%) had platelet counts &gt;400 Gi
l<sup>−1</sup> (range 415–684 Gi l<sup>−1</sup>), the upper limit
of normal. Changes from baseline in these individuals ranged from
32% to 113%. In these subjects, platelet counts decreased to normal
no later than day 117. Because lens changes have been observed in
preclinical animal studies and in clinical studies, ophthalmic
assessments were conducted in this study. No changes in ocular
status due to cataracts were observed during the study.</p>
</div>
</div>
<div id="__sec15" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec15title">Discussion</h2>
<p id="__p46" class="p p-first">This study was conducted because
<em>in vitro</em> data identified eltrombopag as an inhibitor of
both OATP1B1 and BCRP with I<em>C</em><sub>50</sub>s of 2.7
µ<span class="small-caps">m</span> (1.19 µg ml<sup>−1</sup>).
Eltrombopag concentrations achieved clinically are higher than this
I<em>C</em><sub>50</sub> value (<a href=
"/pmc/articles/PMC3162661/table/tbl5/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl5" rid-ob=
"ob-tbl5" co-legend-rid=""><span>Table 5</span></a>), and OATP1B1
and BCRP are important for rosuvastatin disposition. Statins are
widely used cholesterol-lowering agents [<a href="#b13" rid="b13"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901786">13</a>] and are generally used as chronic
therapy, but they are associated with significant toxicities, such
as rhabdomyolysis and increases in liver transaminases, the
incidence of which can increase in the presence of elevated plasma
drug concentrations. In addition, the efficacy of statins can be
reduced if their uptake into the liver is impaired. Thus, drug
interactions involving statins can be clinically important for both
safety and efficacy. The central finding of the study was that
co-administration of eltrombopag 75 mg once daily with a single
dose of rosuvastatin 10 mg increased plasma rosuvastatin
<em>C</em><sub>max</sub> by 103% and AUC(0,∞) by 55% in the overall
study population compared with rosuvastatin alone (<a href=
"/pmc/articles/PMC3162661/table/tbl4/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>).</p>
<p id="__p47">Because it was known that Asian subjects have higher
rosuvastatin exposures than non-Asian subjects [<a href="#b7" rid=
"b7" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901784">7</a>], this study enrolled subjects at one site
in Singapore and one site in the United States. Consistent with
previous data, Asian race was associated with higher plasma
rosuvastatin exposure, with Asian subjects having approximately
twice the exposure as non-Asian subjects enrolled in the current
study when rosuvastatin was given alone. Interestingly, the
non-Asian group studied by Lee <em>et al</em>. [<a href="#b7" rid=
"b7" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901793">7</a>] was composed of White subjects, whereas
the non-Asian group in the current study included a high percentage
of African American subjects. The observed interindividual
variability in plasma rosuvastatin exposure could be due to
different genetic polymorphisms that encode drug-metabolizing
transporters [<a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901796">14</a>]. It was anticipated that inhibition of
OATP1B1 by eltrombopag would have a lesser effect on plasma
rosuvastatin exposure in Asian subjects compared with non-Asian
subjects, whose transporter activity is more functional, and this
was confirmed when the drug interaction results were summarized by
race (<a href="/pmc/articles/PMC3162661/table/tbl4/" target="true"
class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>).</p>
<p id="__p48">OATP1B1 (<em>SLCO1B1</em>) T521C polymorphisms
independently and in combination with the c.388GG polymorphisms
(<em>SLCO1B1</em>*<em>15/</em>*<em>15</em>) have not been
associated with racial differences in rosuvastatin PK, but have
been associated with rosuvastatin PK variability in White subjects
[<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901782">7</a>]. BCRP C421A polymorphisms have been
associated with rosuvastatin PK variability as well [<a href="#b8"
rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901799">8</a>]. The study was not designed to stratify
enrolment by <em>SLCO1B1</em> A388G, <em>SLCO1B</em>1 T521A or
<em>ABCG2</em> C421T genotypes or by <em>SLCO1B1</em> haplotype and
<em>ABCG2</em> C421A genotype combinations. Of the gene variants
evaluated in the current study, only <em>SLCO1B1</em> A388G
genotypes, which have not been independently associated with plasma
rosuvastatin exposure, were relatively evenly distributed across
the enrolled population. In a multivariate analysis where each gene
variant was included separately, genotype was not significantly
associated with plasma rosuvastatin exposure when race, gender and
body weight were included in the model. In multivariate analyses
including <em>SLCO1B1</em> haplotype and <em>ABCG2</em> genotype
combinations, there was some association between haplotype and
genotype combinations and plasma rosuvastatin exposure when race,
gender and body weight were included in the model, but given the
small sample size within each combination, it is difficult to draw
conclusions (<a href="/pmc/articles/PMC3162661/figure/fig02/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure
2</span></a>).</p>
<p id="__p49">The finding of statistically significant higher
plasma rosuvastatin exposures in female subjects has not been
reported in the literature to our knowledge. However, there was a
trend for higher exposures reported for Chinese female healthy
volunteers [<a href="#b15" rid="b15" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901791">15</a>].</p>
<p id="__p50">Because the <em>in vitro</em> inhibition potency of
eltrombopag is similar for OATP1B1 and BCRP and because genetic
polymorphisms in both transporters are known to be associated with
rosuvastatin exposure, it is probable that the increased
rosuvastatin exposure observed with eltrombopag co-administration
is due to inhibition of both transporters. Inhibition of OATP1B1
increases plasma rosuvastatin exposure by reducing the hepatic
uptake; in this scenario, rosuvastatin efficacy may be reduced and
toxicity may be increased. In contrast, inhibition of BCRP
increases plasma rosuvastatin exposure by enhancing rosuvastatin
absorption and/or by inhibiting rosuvastatin elimination in the
bile; in this scenario rosuvastatin efficacy and toxicity may both
be increased. <em>In vitro</em> evidence also suggests that
rosuvastatin is a substrate for other hepatic uptake transporters
including OATP1B3, OATP2B1, OATP1A2, as well as a substrate for the
bile acid uptake transporter NTCP [<a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901795">13</a>]. It is not known if eltrombopag has an
impact on these other transporters.</p>
<p id="__p51">OATP1B1 is highly expressed on the basolateral
(sinusoidal) membrane of hepatocytes and involved in the hepatic
uptake of all HMG-CoA reductase inhibitors (statins) [<a href="#b5"
rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901801">5</a>, <a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901779">13</a>]. However, the importance of OATP1B1 on
the HMG-CoA reductase inhibitors' disposition varies among the
drugs of this class. For example, subjects with the homozygous
OATP1B1 (<em>SLCO1B1</em>) 521CC genotype had 1.65- to 3.21-fold
higher exposures of rosuvastatin, pravastatin, simvastatin,
lovastatin and atorvastatin than those with the homozygous 521TT
(control) genotypes [<a href="#b6" rid="b6" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901781">6</a>,
<a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901802">16</a>, <a href="#b17" rid="b17" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901776">17</a>]. In contrast, fluvastatin exposure was
not different among the T521C genotypes, further suggesting that
OATP1B1 may not be important for fluvastatin disposition. BCRP is
highly expressed on the apical membrane of enterocytes of the small
intestine and the bile canalicular membrane of the hepatocyte and
involved in the efflux of some statins out of the intestine and
into the bile. BCRP polymorphisms have been associated with
rosuvastatin, atorvastatin, fluvastatin and simvastatin lactone
(but not acid), but not pravastatin or pitavastatin [<a href="#b8"
rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901798">8</a>, <a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901780">9</a>,
<a href="#b18" rid="b18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901789">18</a>, <a href="#b19" rid="b19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901797">19</a>].</p>
<p id="__p52">Given that exposures to several HMG-CoA reductase
inhibitors are associated with OATP1B1 (<em>SLCO1B1</em>) and/or
BCRP (<em>ABCG2</em>) polymorphisms, the results of the
eltrombopag-rosuvastatin interaction study may be extended to other
statins. In subjects who were co-administered eltrombopag and
rosuvastatin, increased rosuvastatin <em>C</em><sub>max</sub> (mean
103% increase) and AUC(0,∞) (mean 55% increase) were observed. This
suggests that clinicians should consider reducing a subject's dose
of statin when co-administered with eltrombopag. Monitoring side
effects, clinical chemistry, and lipid concentrations is warranted
in subjects receiving both eltrombopag and a statin. As noted by
other investigators, most clinically significant drug–drug
interactions involving lipid-lowering drugs can be avoided by
appropriate drug selection and dosing [<a href="#b5" rid="b5"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901787">5</a>].</p>
<p id="__p53">The impact of rosuvastatin on plasma eltrombopag PK
was not formally assessed. However, eltrombopag trough
concentrations collected prior to co-administration of rosuvastatin
were similar to trough concentrations collected 24 h after
co-administration of a single dose of rosuvastatin. In addition,
plasma eltrombopag exposure for the 75 mg once daily regimen (in
combination with a single dose of rosuvastatin) was generally as
expected based on plasma eltrombopag exposures observed in other
eltrombopag studies [<a href="#b20" rid="b20" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_230901794">20</a>–<a href="#b22" rid="b22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_310502497">22</a>]. Therefore, there does not appear to be a
significant impact of rosuvastatin on plasma eltrombopag PK.</p>
<p id="__p54">Plasma eltrombopag exposures collected in the
presence of rosuvastatin were similar between Asian and non-Asian
subjects. This is inconsistent with previous studies that have
shown approximately two-fold higher plasma eltrombopag exposures in
Asian <em>vs.</em> non-Asian subjects [<a href="#b21" rid="b21"
class=" bibr popnode">21</a>, <a href="#b22" rid="b22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_310502495">22</a>]. In these prior studies, the non-Asian
populations were predominantly White/Caucasian, whereas, in the
current study, the non-Asian population included a high percentage
of African Americans. Within the non-Asian population, female
subjects had higher plasma eltrombopag exposure, which is
consistent with previous reports [<a href="#b22" rid="b22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_310502496">22</a>]. Eltrombopag is a BCRP substrate and
plasma eltrombopag exposure was similar between c.421CC and c.421CA
genotypes. Although the one subject (Asian male) with the c.421AA
genotype had the highest plasma eltrombopag AUC(0,τ) (247 µg
ml<sup>−1</sup> h), the exposure was similar to the highest
AUC(0,τ) (227 µg ml<sup>−1</sup> h) observed for an Asian male
subject with the c.421CC genotype. Given the limited data for the
c.421AA genotype, no conclusions can be drawn as to whether this
genotype is associated with plasma eltrombopag exposure.</p>
<p id="__p55" class="p p-last">In conclusion, concomitant
administration of eltrombopag with rosuvastatin was associated with
increased rosuvastatin exposure. The therapeutic index of HMG Co-A
reductase inhibitors may be reduced by the concomitant use of
eltrombopag. In subjects taking eltrombopag, a reduced dose of HMG
Co-A reductase inhibitors may be needed.</p>
</div>
<div id="__ackid844512" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid844512title">
Acknowledgments</h2>
<div class="sec">
<p id="__p56">The authors thank Mark Dana, Sandra Saouaf, PhD and
AOI Communications, L.P., for assistance in preparing this
manuscript.</p>
</div>
</div>
<div id="__sec16" class="tsec bk-sec">
<h2 class="head no_bottom_margin" id="__sec16title">Competing
Interests</h2>
<!--/article/back/sec/-->
<p id="__p57" class="p p-first-last">Alicia Allred, Carolyn Bowen
and Mary Beth Wire are employees of GlaxoSmithKline (GSK), and are
stock holders. Bin Peng and Jung Wook Park were employees of GSK
during the time that the study was conducted, and are stock
holders. Daphne Williams was an employee of GSK during the time
that the study was conducted. Edmund Lee does not have conflicts of
interest to disclose.</p>
</div>
<div id="__ref-listid844533" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid844533title">
REFERENCES</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"element-citation">Bussel JB, Provan D, Shamsi T, Cheng G, Psaila
B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone
N, Arning M. Effect of eltrombopag on platelet counts and bleeding
during treatment of chronic idiopathic thrombocytopenic purpura: a
randomised, double-blind, placebo-controlled trial.
<span><span class="ref-journal">Lancet.</span> 2009;<span class=
"ref-vol">373</span>:641–8.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/19231632" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"element-citation">Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva
L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M,
Provan D, Jenkins JM. Eltrombopag for the treatment of chronic
idiopathic thrombocytopenic purpura. <span><span class=
"ref-journal">N Engl J Med.</span> 2007;<span class=
"ref-vol">357</span>:2237–47.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/18046028" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"element-citation">McHutchison JG, Dusheiko G, Shiffman ML,
Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC,
Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH.
Eltrombopag for thrombocytopenia in patients with cirrhosis
associated with hepatitis C. <span><span class="ref-journal">N Engl
J Med.</span> 2007;<span class="ref-vol">357</span>:2227–36.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/18046027" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"element-citation">Erickson-Miller CL, Delorme E, Tian SS, Hopson
CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo
JI, Duffy KJ, Jenkins JM. Preclinical activity of eltrombopag
(SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
<span><span class="ref-journal">Stem Cells.</span>
2009;<span class="ref-vol">27</span>:424–30.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC2729672/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/19038790" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"element-citation">Neuvonen PJ, Niemi M, Backman JT. Drug
interactions with lipid-lowering drugs: mechanisms and clinical
relevance. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2006;<span class="ref-vol">80</span>:565–81.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/17178259" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"element-citation">Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M.
Different effects of SLCO1B1 polymorphism on the pharmacokinetics
of atorvastatin and rosuvastatin. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 2007;<span class=
"ref-vol">82</span>:726–33.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/17473846" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"element-citation">Lee E, Ryan S, Birmingham B, Zalikowski J, March
R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin
pharmacokinetics and pharmacogenetics in white and Asian subjects
residing in the same environment. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 2005;<span class=
"ref-vol">78</span>:330–41.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/16198652" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"element-citation">Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang
A, Liu YL, Tan ZR, Fen J, Huang YF, Zhou HH. Role of BCRP 421C&gt;A
polymorphism on rosuvastatin pharmacokinetics in healthy Chinese
males. <span><span class="ref-journal">Clin Chim Acta.</span>
2006;<span class="ref-vol">373</span>:99–103.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/16784736" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"element-citation">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ,
Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the
pharmacokinetics of atorvastatin and rosuvastatin.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
2009;<span class="ref-vol">86</span>:197–203.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/19474787" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"element-citation">Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon
EW, Ko GT, Baum L, Tam LS, Li EK. ABCG2 polymorphism is associated
with the low-density lipoprotein cholesterol response to
rosuvastatin. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2010;<span class="ref-vol">87</span>:558–62.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/20130569" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"element-citation">Schneck DW, Birmingham BK, Zalikowski JA,
Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS,
Raza A. The effect of gemfibrozil on the pharmacokinetics of
rosuvastatin. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2004;<span class="ref-vol">75</span>:455–63.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/15116058" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"element-citation">Simonson SG, Raza A, Martin PD, Mitchell PD,
Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin
pharmacokinetics in heart transplant recipients administered an
antirejection regimen including cyclosporine. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 2004;<span class=
"ref-vol">76</span>:167–77.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15289793" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"element-citation">Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W,
Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in
rosuvastatin hepatic uptake: function, expression, and
pharmacogenetics. <span><span class=
"ref-journal">Gastroenterology.</span> 2006;<span class=
"ref-vol">130</span>:1793–806.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/16697742" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"element-citation">Smith NF, Figg WD, Sparreboom A. Role of the
liver-specific transporters OATP1B1 and OATP1B3 in governing drug
elimination. <span><span class="ref-journal">Expert Opin Drug Metab
Toxicol.</span> 2005;<span class="ref-vol">1</span>:429–45.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/16863454" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"element-citation">Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q.
Pharmacokinetic properties of rosuvastatin after single-dose, oral
administration in Chinese volunteers: a randomized, open-label,
three-way crossover study. <span><span class="ref-journal">Clin
Ther.</span> 2007;<span class="ref-vol">29</span>:2194–203.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/18042475" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"element-citation">Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1
polymorphism and sex affect the pharmacokinetics of pravastatin but
not fluvastatin. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2006;<span class="ref-vol">80</span>:356–66.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/17015053" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"element-citation">Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M.
SLCO1B1 polymorphism markedly affects the pharmacokinetics of
simvastatin acid. <span><span class="ref-journal">Pharmacogenet
Genomics.</span> 2006;<span class="ref-vol">16</span>:873–9.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/17108811" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"element-citation">Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M.
Different effects of the ABCG2 c.421C&gt;A SNP on the
pharmacokinetics of fluvastatin, pravastatin and simvastatin.
<span><span class="ref-journal">Pharmacogenomics.</span>
2009;<span class="ref-vol">10</span>:1617–24.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/19842935" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"element-citation">Ieiri I, Suwannakul S, Maeda K, Uchimaru H,
Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S,
Higuchi S, Sugiyama Y. SLCO1B1 (OATP1B1, an uptake transporter) and
ABCG2 (BCRP, an efflux transporter) variant alleles and
pharmacokinetics of pitavastatin in healthy volunteers.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
2007;<span class="ref-vol">82</span>:541–7.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/17460607" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"element-citation">Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen
V, Collins D, Erickson-Miller CL. Phase 1 clinical study of
eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
<span><span class="ref-journal">Blood.</span> 2007;<span class=
"ref-vol">109</span>:4739–41.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/17327409" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"element-citation">PROMACTA® (eltrombopag) <span class=
"ref-journal">Full Prescribing Information.</span> Research
Triangle Park, NC: GlaxoSmithKline; 2008.</span></div>
<div class="ref-cit-blk half_rhythm" id="b22">22. <span class=
"element-citation">Gibiansky E, Zhang J, Williams D, Wang Z,
Ouellet D. Population pharmacokinetics of eltrombopag in healthy
subjects and patients with chronic idiopathic thrombocytopenic
purpura. <span><span class="ref-journal">J Clin Pharmacol.</span>
2010</span> [Epub ahead of print] <span class=
"nowrap ref pubmed">[<a href="/pubmed/20663993" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC3162661/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC3162661/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC3162661/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC3162661/pdf/bcp0072-0321.pdf">PDF
(1.1M)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC3162661" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F&amp;text=Eltrombopag%20increases%20plasma%20rosuvastatin%20exposure%20in%20healthy%20volunteers">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="21434975" data-aiid="3162661"
data-aid="3162661" data-iid="199617" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC3162661" data-md5=
"051ac9b28a0b897031d6bc46e4e5851f"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-16T15:42:38-04:00&amp;Host=ptpmc101">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC3162661/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- 8A1A5178763012E1_0185SID /projects/PMC/PMCViewer@4.35 ptpmc101 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
